Purple Biotech to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Purple Biotech (NASDAQ/TASE: PPBT) announced a corporate overview presentation at the Jefferies London Healthcare Conference on November 16, 2022, at 7:25 am GMT. The presentation will cover the Company’s clinical development programs, including therapies targeting tumor immune evasion and drug resistance. Noteworthy projects include NT219, a dual inhibitor currently in Phase 1/2 trials, and CM24, a monoclonal antibody in Phase 2 studies. Both therapies are key components of Purple Biotech's oncology pipeline aimed at enhancing cancer treatment effectiveness.

REHOVOT, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that Gil Efron, Chief Executive Officer of Purple Biotech, and Fabien Sebille, Chief Business Officer, will present a corporate overview of the Company’s clinical development programs at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 7:25 am GMT. The conference will take place from November 15-17, 2022, and Mr. Efron and Mr. Sebille will be available for one-on-one meetings.

Jefferies London Healthcare Conference - November 15-17, 2022

Date: Wednesday, November 16, 2022
Time: 7:25-7:55 am GMT

About Purple Biotech  

Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing NT219 as a monotherapy treatment of solid tumors, and in a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma. These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The Company’s corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purple-biotech.com/.

CONTACTS:

Company Contact:
Lior Fhima
Chief Financial Officer
IR@purple-biotech.com

Media Inquiries 
Anna Army 
Account Supervisor, Integrated Communications 
LaVoieHealthScience 
T: 617-351-0246 
aarmy@lavoiehealthscience.com 

###

FAQ

What is the date and time of Purple Biotech's presentation at the Jefferies London Healthcare Conference?

Purple Biotech will present on November 16, 2022, at 7:25 am GMT.

What is the focus of Purple Biotech's clinical development programs?

The focus is on developing therapies that overcome tumor immune evasion and drug resistance.

What are the main therapies highlighted by Purple Biotech?

The main therapies include NT219, a dual inhibitor, and CM24, a monoclonal antibody.

What clinical trials are currently ongoing for NT219?

NT219 is undergoing Phase 1/2 trials as a monotherapy and in combination with cetuximab.

How is CM24 being tested in clinical studies?

CM24 is being tested in a Phase 2 study in combination with anti-PD-1 checkpoint inhibitors for pancreatic cancer.